CRDF Cardiff Oncology Inc

Price (delayed)

$3.99

Market cap

$178.26M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.93

Enterprise value

$158.76M

Cardiff Oncology is a clinical-stage biotechnology company with the singular mission of developing new treatment options for cancer patients in indications with the greatest medical need. Its goal is to ...

Highlights

The gross profit has increased by 26% YoY and by 6% QoQ

Cardiff Oncology's revenue has increased by 26% YoY and by 6% from the previous quarter

The quick ratio has contracted by 47% YoY and by 20% from the previous quarter

The equity has declined by 34% year-on-year and by 10% since the previous quarter

Sector: Healthcare

Industry: Biotechnology

Website: http://cardiffoncology.com

Peers: OMER OMGA

Key stats

What are the main financial stats of CRDF

Market

Shares outstanding

44.68M

Market cap

$178.26M

Enterprise value

$158.76M

Valuations

Price to earnings (P/E)

N/A

Price to book (P/B)

2.56

Price to sales (P/S)

365.29

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

325.32

Earnings

Revenue

$488,000

EBIT

-$41.44M

EBITDA

-$41.04M

Free cash flow

-$31.47M

Per share

EPS

-$0.93

Free cash flow per share

-$0.7

Book value per share

$1.56

Revenue per share

$0.01

TBVPS

$1.83

Balance sheet

Total assets

$81.64M

Total liabilities

$11.9M

Debt

$2.15M

Equity

$69.74M

Working capital

$66.97M

Liquidity

Debt to equity

0.03

Current ratio

7.41

Quick ratio

7.19

Net debt/EBITDA

0.48

Margins

EBITDA margin

-8,410.5%

Gross margin

100%

Net margin

-8,492%

Operating margin

-9,305.7%

Efficiency

Return on assets

-44.3%

Return on equity

-50.2%

Return on invested capital

-60.2%

Return on capital employed

-58.2%

Return on sales

-8,492%

Dividend

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

CRDF stock price

How has the Cardiff Oncology stock price performed over time

Intraday

-4.55%

1 week

-8.7%

1 month

-32.49%

1 year

166%

YTD

169.59%

QTD

-25.28%

Financial performance

How have Cardiff Oncology's revenue and profit performed over time

Revenue

$488,000

Gross profit

$488,000

Operating income

-$45.41M

Net income

-$41.44M

Gross margin

100%

Net margin

-8,492%

The gross profit has increased by 26% YoY and by 6% QoQ

Cardiff Oncology's revenue has increased by 26% YoY and by 6% from the previous quarter

Cardiff Oncology's net margin has increased by 15% YoY and by 4.3% QoQ

CRDF's operating income is down by 14% year-on-year and by 2.1% since the previous quarter

Growth

What is Cardiff Oncology's growth rate over time

Valuation

What is Cardiff Oncology stock price valuation

P/E

N/A

P/B

2.56

P/S

365.29

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

325.32

Cardiff Oncology's EPS has decreased by 4.5% YoY

The equity has declined by 34% year-on-year and by 10% since the previous quarter

The stock's price to book (P/B) is 34% more than its 5-year quarterly average of 2.0

The P/S is 148% more than the last 4 quarters average of 154.1 and 4.8% more than the 5-year quarterly average of 365.1

Cardiff Oncology's revenue has increased by 26% YoY and by 6% from the previous quarter

Efficiency

How efficient is Cardiff Oncology business performance

The company's return on invested capital has shrunk by 61% YoY and by 18% QoQ

Cardiff Oncology's return on equity has shrunk by 52% YoY and by 13% QoQ

CRDF's return on assets is down by 46% year-on-year and by 11% since the previous quarter

Cardiff Oncology's return on sales has increased by 15% YoY and by 4.3% QoQ

Dividends

What is CRDF's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for CRDF.

Financial health

How did Cardiff Oncology financials performed over time

The company's current ratio fell by 48% YoY and by 20% QoQ

The quick ratio has contracted by 47% YoY and by 20% from the previous quarter

Cardiff Oncology's debt is 97% lower than its equity

The equity has declined by 34% year-on-year and by 10% since the previous quarter

Cardiff Oncology's debt has decreased by 21% YoY and by 6% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.